| Value | ₹2.50 Cr |
|---|---|
| Execution period | 3 years from vesting |
BSE filing, NSE: SOMDUTTFIN. Summary written from the filing by ALFA Finder's alert engine.
Crescentis Capital Ltd: key numbers
- Share price
- ₹101.00
- Market cap
- ₹171.8 Cr
- Revenue (annual)
- ₹1.48 Cr
- Net profit (annual)
- ₹-2.53 Cr
- P/E (TTM)
- 145.9×Sector 19.7×
- Promoter holding
- 74.98%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Crescentis Capital Ltd
All →Crescentis Capital Board Meeting Date
Crescentis Capital will hold a Fund-Raising Committee meeting on 29 October 2026 to approve the terms of a proposed rights issue of up to Rs 80 crore. The filing is a prior intimation of that committee meeting.
Crescentis Capital Other Announcement
Crescentis Capital Limited submitted the Reconciliation of Share Capital Audit Report for the quarter ended September 30, 2026, as per SEBI regulations.
Crescentis Capital Other Announcement
Crescentis Capital Ltd submitted its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI regulations.
Crescentis Capital Employee Stock Options
Crescentis Capital Limited granted 5,00,000 stock options to its Managing Director, Mr. Subba Rao Veeravenkata Meka, under the company's 2025 ESOS scheme.
Crescentis Capital Fund Raise of ₹80 Cr
Crescentis Capital Limited's board has approved a rights issue of equity shares for up to Rs 80 Crore. The board also approved the Draft Letter of Offer.
- Value
- ₹80.00 Cr
Crescentis Capital Board Meeting Date
Crescentis Capital will hold a board meeting on September 29, 2026, to discuss progress on its proposed rights issue of equity shares.
Other employee stock options announcements
All →Aye Finance Employee Stock Options
Aye Finance's employee welfare trust transferred 89,501 equity shares to grantees on exercising ESOP options. The share capital remains unchanged, so no new issuance occurs.
Aarti Pharmalabs Employee Stock Options
Aarti Pharmalabs granted 850 stock options to employees under its PSOP 2023 at Rs.5 exercise price. This is an employee incentive grant, not a capital raise.
OnEMI Technology Solutions Employee Stock Options
OnEMI Technology allotted 69,000 equity shares on exercise of employee stock options under the Kissht ESOP 2022 plan. The shares rank pari passu with existing equity.
Bliss GVS Pharma Employee Stock Options
Bliss GVS Pharma seeks shareholder approval via postal ballot for new employee stock option plans 2026. Up to 26,50,000 options are proposed; voting closes November 27, 2026.
Bandhan Bank Employee Stock Options
Bandhan Bank's board granted 32,98,871 stock options under ESOP Series 1 (Tranche 9) at Rs 151.91 per option. The options vest over four years, with each option convertible into one equity share.
Maxvolt Energy Industries Employee Stock Options
Maxvolt Energy granted 5,01,726 ESOPs to six employees under its MEIL ESOP 2025 scheme at exercise prices of ₹30 and ₹45. Options vest over four years, with exercise windows following vesting.
- Execution
- Vesting over 4 years from grant (25% at 2nd, 25% at 3rd, 50% at 4th anniversary); exercise over 3 years from each vesting date